ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0095

Association of Urban vs. Rural Residence with New DMARD Initiation in US Veterans with Active Rheumatoid Arthritis

Luke Desilet1, Harlan Sayles1, Punyasha Roul2, Jennifer Barton3, Gail Kerr4, Kaleb Michaud1, Ted Mikuls5 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC, Omaha, NE, 3VA Portland Health Care System/OHSU, Portland, OR, 4Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 5Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2022

Keywords: Disparities, Epidemiology, quality of care, rheumatoid arthritis, socioeconomic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Healthcare Disparities in Rheumatology Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: While a treat-to-target strategy is endorsed by the ACR RA Treatment Guidelines, many patient, social, and healthcare system factors make implementation of this approach challenging in real-world clinical settings. Rural residence has been associated with disparities in healthcare-related outcomes in both rheumatic diseases and other chronic conditions. Thus, we examined whether urban vs. rural residence was associated with the frequency of new DMARD initiations among US Veterans with persistently active RA.

Methods: We performed a cohort study of US Veterans with RA in the Veterans Affairs Rheumatoid Arthritis (VARA) registry between 2003 and 2020. We identified patients with persistently active RA (2 consecutive visits with moderate or high disease activity by DAS28) who did not initiate a new DMARD between visits. Urban or rural residence was based on Veterans Health Administration (VHA) maintained residential address urban/rural categorization. The primary outcome was initiation of a new DMARD (not utilized at the last 2 visits) within 1 year of the index visit, defined as the second date of moderate-to-high disease activity.  Secondary outcomes were new initiations of specific DMARD categories (conventional synthetic DMARDs, TNFi biologic DMARDs, and non-TNFi biologic/targeted synthetic DMARDs). Multivariable logistic regression models included age, sex, race, education, smoking status, anti-CCP status, RA disease duration, BMI, Rheumatic Disease Comorbidity Index (RDCI), VARA site, calendar year (2003-2010 vs. 2011-2020), baseline DAS28, number of prior DMARDs, and prednisone use.

Results: We identified 1,461 patients with persistently active RA who did not recently initiate a new DMARD during our observation period. Patients were predominantly male (89%) and had a mean (SD) age of 71.4 (10.2) years (Table 1). Overall, 902 (62%) patients resided in urban areas and 559 (38%) resided in rural areas. Rural patients were more likely than urban counterparts to be male, white, current smokers and they had more baseline prednisone and prior DMARD use (Table 1). The proportion of patients initiating any new DMARD over the following year was similar between urban (n=363, 40%) and rural (n=234, 42%) patients. Following multivariable adjustment, no association was observed between urban vs. rural residence and new DMARD initiation (aOR 1.19 [0.87, 1.64]; Table 2). Similarly, no significant associations were observed between urban vs. rural residence and initiation of specific DMARD categories (conventional synthetic DMARDs, TNFi biologic DMARDs, and non-TNFi biologic/targeted synthetic DMARDs) after adjustment for covariates (Table 3).

Conclusion: Using real-world data from a multicenter observational RA cohort, we found that less than half of US Veterans with RA were prescribed a new DMARD in the setting of persistently active disease. Rates of new DMARD initiation did not differ between those in urban and rural areas, suggesting that within the VHA system, urban-rural health disparities are not responsible for difficulties implementing a treat-to-target strategy. Additional interventions are needed to improve implementation of treat-to-target strategies for RA regardless of rurality.

Supporting image 1

Patient characteristics by urban or rural residence.

Supporting image 2

Association of urban vs. rural residence and incident new DMARD initiation in patients with persistently active RA

Supporting image 3

Association of urban vs. rural residence and incident new DMARD initiation in patients with persistently active RA – by DMARD category


Disclosures: L. Desilet, None; H. Sayles, None; P. Roul, None; J. Barton, None; G. Kerr, Pfizer, Janssen; K. Michaud, None; T. Mikuls, Gilead Sciences, Bristol-Myers Squibb, Horizon, Sanofi, Pfizer Inc; B. England, Boehringer-Ingelheim.

To cite this abstract in AMA style:

Desilet L, Sayles H, Roul P, Barton J, Kerr G, Michaud K, Mikuls T, England B. Association of Urban vs. Rural Residence with New DMARD Initiation in US Veterans with Active Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/association-of-urban-vs-rural-residence-with-new-dmard-initiation-in-us-veterans-with-active-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-urban-vs-rural-residence-with-new-dmard-initiation-in-us-veterans-with-active-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology